Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
Licensing
Argenx (ARGX) stock yo-yoed Wednesday, briefly edging above its 21-day line, as investors digested its myositis-focused R&D Day. Myositis causes inflammation of the skeletal muscles. But, instead of focusing on a broad group of all patients, Argenx is testing its bread-and-butter drug, Vyvgart, in two subgroups. Immune-mediated necrotizing myopathy, or IMNM, causes progressive muscle weakness. Dermatomyositis, also called DM, leads…
